Chemoprevention of breast cancer: The Italian experience

Journal of Cellular Biochemistry

Volumn 77, Issue SUPPL. 34, 2000, Pages 84-96

  Decensi, Andrea ^a   Bonanni, Bernardo ^a   Guerrieri Gonzaga, Aliana ^a   Torrisi, Rosalba ^a   Manetti, Lapo ^a   Robertson, Chris ^a   De Palo, Giuseppe ^b   Formelli, Franca ^b   Costa, Alberto ^a   Veronesi, Umberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Chemoprevention; Fenretinide; IGF I; Surrogate biomarkers; Tamoxifen

Indexed keywords

FENRETINIDE; SOMATOMEDIN; SOMATOMEDIN C; TAMOXIFEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; ITALY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHLEBITIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; REVIEW; SKIN DISEASE; BREAST TUMOR; METABOLISM; PATIENT SELECTION;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; FEMALE; FENRETINIDE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; ITALY; MAMMOGRAPHY; MULTICENTER STUDIES; PATIENT SELECTION; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0034033556     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(2000)77:34+<84::AID-JCB15>3.0.CO;2-7     Document Type: Review

References (19)

1. Adamo ML, Shao ZM, Lanau F, Chen CC, Clemmons DR, Roberts CT Jr, LeRoith D, Fontana JA. 1992. Insulin-like Growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding protein (IGFBPs): IGFBP-2,-3,-4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 131:1858-1866.
2. Baserga R. 1995. The insulin-like growth factors I receptor: a key to tumor growth? Cancer Res 55:249-252.
3. Bonneterre J, Peyrat JP, Beuscart R, Demaille A. 1990. Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res 50:6931-6936.
4. Boyd NF, Jensen HM, Cooke G, Han HL. 1992. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 84:1170-1179.
5. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ. 1995a. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87:670-675.
6. Boyd NF, Fishell E, Jong R, MacDonald JC, Sparrow RK, Simor IS, Kriukov V, Lockwood G, Tritchler D. 1995b. Mammographic densities as a criterion for entry to a clinical trial of breast cancer prevention. Br J Cancer 72:476-479.
7. Boyd NF, Greenberg C, Lockwood G, Little L, Martin L, Byng J, Yaffe M, Tritchler D. 1997. Effects at two years of a low-fat, high-carbohydrate diet on radiological features of the breast: results from a randomized trial. J Natl Cancer Inst 89:488-496.
8. Bruning PF, Bonfrer JMG, van Noord PAH, Hart AAM, de Jong-Bakker M, Nooijen WJ. 1992. Insulin resistance and breast cancer risk. Int J Cancer 52:511-516.
9. Buckley MMT, Goa KL. 1989. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37:451-490.
10. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R. 1995. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87:1622-1629.
11. Cobleigh MA, Dowlatshahi K, Deutsch TA, Metha RG, Moon RC, Minn F, Benson AB III, Rademaker AW, Ashen hurst JB, Wade JL III, Wolter J. 1993. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11:474-477.
12. Costa A, Malone W, Perloff M, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M, Andreoli C, Del Vecchio M, Formelli F, Barbieri A. 1989. Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 25:805-808.
13. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U. 1994. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54(suppl):2032-2037.
14. De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Rosselli del Turco M, Decensi A, D'Aiuto G, Veronesi U. 1997. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 83:884-893.
15. de Waard F. 1979. Premenopausal and postmenopausal breast cancer: one disease or two?. J Natl Cancer Inst 63:549-550.
16. Decensi A, Torrisi R, Polizzi A, Gesi R, Brezzo V, Rolando M, Rondanina G, Orengo MA, Formelli F, Costa A. 1994. Effect of the synthetic retinoid fenretinide on darkadaptation and the ocular surface. J Natl Cancer Inst 86:105-110.
17. Decensi A, Costa A, De Palo G, Formelli F, Marubini E, Mariani L, Fontana V, Veronesi U. 1997. Retinoid-estrogen interactions in a breast cancer prevention trial. Proc AACR 38:529.
18. Decensi A, Robertson C, Rotmensz N, Severi G, Maisonneuve P, Sacchini V, Boyle P, Costa A, Veronesi U for the Italian Tamoxifen prevention trial. 1998a. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Br J Cancer (in press).
19. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A, Umberto Veronesi. 1998b. Biological effects of tamoxifen at low doses in healthy women. Natl Cancer Inst (in press).